Journal article
Reproducibility and repeatability of semiquantitative 18F-Fluorodihydrotestosterone uptake metrics in castration-resistant prostate cancer metastases: A prospective multicenter study
HA Vargas, GM Kramer, AM Scott, A Weickhardt, AA Meier, N Parada, BJ Beattie, JL Humm, KD Staton, PB Zanzonico, SK Lyashchenko, JS Lewis, M Yaqub, RE Sosa, AJ Van Den Eertwegh, ID Davis, U Ackermann, K Pathmaraj, RC Schuit, AD Windhorst Show all
Journal of Nuclear Medicine | SOC NUCLEAR MEDICINE INC | Published : 2018
Abstract
18F-fluorodihydrotestosterone (18F-FDHT) is a radiolabeled analog of the androgen receptor's primary ligand that is currently being credentialed as a biomarker for prognosis, response, and pharmacodynamic effects of new therapeutics. As part of the biomarker qualification process, we prospectively assessed its reproducibility and repeatability in men with metastatic castration-resistant prostate cancer. Methods: We conducted a prospective multiinstitutional study of metastatic castration-resistant prostate cancer patients undergoing 2 (test/retest) 18F-FDHT PET/CT scans on 2 consecutive days. Two independent readers evaluated all examinations and recorded SUVs, androgen receptor-positive tum..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
This study was funded by a Movember Foundation Global Action Plan award. Memorial Sloan Kettering Cancer Center is supported by NIH/NCI Cancer Center Support Grant P30 CA008748. No other potential conflict of interest relevant to this article was reported.